Stayble Therapeutics AB (“Stayble” or “the Company”) announced today that the last patient visit has been completed in the phase 1b study involving patients with pain caused by herniated discs. This company follows the previously communicated timeline and expects to present results during the fourth quarter of 2024.
Latest press releases
September 5, 2024
Read more
Stayble receives its first approved patent for the treatment of herniated discs
Stayble Therapeutics AB (“Stayble” or “the Company”) announced today that the South African patent office, as the first country, has approved the Company’s patent for the treatment of herniated discs with STA363. This approval is a significant milestone for the Company and follows a previous positive international search report from European authorities. With these advancements, we see strong potential to obtain several additional national patent approvals.
August 20, 2024 Regulatorisk
Read more
Stayble Therapeutics publishes half-year report for 2024
Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its half-year report for 2024. The report is available as an attached document and on the Company’s website: https://staybletherapeutics.com/investor-relations/financial-reports/. Below is a summary of the report.
July 23, 2024 Regulatorisk
Read more
Stayble Therapeutics appoints new CFO
Stayble Therapeutics AB announces that Erik Kullgren has been appointed as the new CFO, effective August 1, 2024.
Press photos
In need of press photos? Contact us for a curated collection of images and logotypes approved for use in editorial purposes.
Get all the latest news
Or connect with us on social media
LATEST ARTICLES AND COMPANY ANALYSIS
INVEST IN THE FUTURE TREATMENT OF CHRONIC BACK AND LEG PAIN
Stayble is listed on Nasdaq First North under the ticker STABL. You will find all relevant information on the Stayble share in our Investors section.
Investors